Become A Wiser, More Profitable Investor

Delcath Systems: Prepare For Substantial Dilution Post-FDA Approval For Hepzato Kit - Seeking Alpha

Delcath Systems (NASDAQ:DCTH) announced that the FDA approved its HEPZATO Kit device as a treatment for a type of liver-dominant eye cancer. The stock shot up to over $7.00 in early afternoon trading on Tuesday as the device is expected to be launched by the end of the year. Fellow Seeking Alpha contributor TripleGate astutely called the FDA approval a few days ago, and is likely rolling in substantial and immediate profits thanks to it. While the assessment of the probability of FDA approval was well covered, one thing that the author did not account for or discuss was existing and coming dilution.

seekingalpha.com     Aug 16, 2023